Understanding Hemophilia A: Genetics, Severity, and Diagnosis

Receiving a diagnosis of Hemophilia A can feel overwhelming, but understanding the biology and genetics of the condition is the first step toward managing it effectively. Hemophilia A is a lifelong but treatable genetic disorder that affects how the blood clots ^[1].

Three Stabilizing Facts about Hemophilia A

• It is manageable: With modern treatments, most people with Hemophilia A live full, active lives with a near-normal life expectancy.
• It is not anyone’s “fault”: About 1 in 3 cases occur as a de novo (spontaneous) mutation, meaning there was no family history and no way to predict it ^[2][3].
• Severity is predictable: Your “factor level” tells your care team a great deal about what to expect and how to prevent bleeding before it starts.

The Role of Factor VIII: The “Spark” of Clotting

To understand Hemophilia A, it helps to think of the blood clotting process (the coagulation cascade) as a series of chemical reactions. Factor VIII (8) is a vital protein that acts as a cofactor—essentially a helper that speeds up the process ^[4].

Specifically, Factor VIII joins forces with another protein, Factor IX, to create a specialized mechanism that eventually leads to the formation of a stable blood clot. Without enough functional Factor VIII, this process works incredibly slowly—up to 200,000 times slower than normal—making it difficult for the body to stop bleeding ^[5].

Understanding Severity Levels

Doctors classify Hemophilia A based on the amount of Factor VIII activity in your blood. A person without hemophilia typically has 50% to 150% activity. In Hemophilia A, these levels are much lower:

Current guidelines emphasize that while these percentages provide a framework, your phenotype (how you actually bleed) is just as important as the number ^[6]. Some people with “moderate” levels may bleed like those with “severe” levels and may still need preventative treatment ^[9].

The Genetics: Why It Happened

Hemophilia A is caused by a mutation in the F8 gene, located on the X chromosome ^[1].

• X-Linked Inheritance: Because the gene is on the X chromosome, the condition primarily affects males (who have one X and one Y). Females (who have two X chromosomes) are usually “carriers.” However, current medical consensus recognizes that some carriers have low enough Factor VIII levels (5% to 40%) to be diagnosed with mild hemophilia themselves ^[7][10]. For these female patients, bleeding risks become particularly relevant during heavy menstruation or childbirth.
• De Novo Mutations: In roughly 30% to 33% of new diagnoses, the mutation happens spontaneously during the development of the egg or sperm ^[2]. In these cases, there is no previous history of hemophilia in the family ^[3].

Congenital vs. Acquired Hemophilia

It is important to distinguish congenital Hemophilia A (which you are born with) from acquired Hemophilia A.

• Congenital: An inherited or spontaneous genetic change present from birth ^[11].
• Acquired: A very rare autoimmune condition where the immune system suddenly starts attacking the body’s own Factor VIII ^[11]. This typically happens later in life and is not caused by the F8 gene mutation ^[12][13].

Diagnosis is confirmed through specialized blood tests, including factor assays to measure activity levels and genetic testing to identify the specific mutation in the F8 gene ^[14][15].